Cobimetinib has 10 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 9 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Levoketoconazole, Carbamazepine, Ciprofloxacin. Patients taking Cobimetinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 10
- Contraindicated
- 1
- Major
- 9
Contraindicated (1)
- Cobimetinib + Levoketoconazole— Concomitant use is contraindicated due to increased risk of QT prolongation and torsades de pointes.
Major (9)
- Cobimetinib + Carbamazepine— Strong CYP3A inducer may decrease cobimetinib exposure by >80% and reduce efficacy. Avoid concurrent use.
- Cobimetinib + Ciprofloxacin— Moderate CYP3A inhibitor. If short-term use unavoidable, reduce cobimetinib dose from 60 mg to 20 mg.
- Cobimetinib + Efavirenz— Strong CYP3A inducer may decrease cobimetinib exposure by >80% and reduce efficacy. Avoid concurrent use.
- Cobimetinib + Erythromycin— Moderate CYP3A inhibitor. If short-term use unavoidable, reduce cobimetinib dose from 60 mg to 20 mg.
- Cobimetinib + Itraconazole— Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib La…
- Cobimetinib + Phenytoin— Strong CYP3A inducer may decrease cobimetinib exposure by >80% and reduce efficacy. Avoid concurrent use.
- Cobimetinib + Rifampin— Strong CYP3A inducer may decrease cobimetinib exposure by >80% and reduce efficacy. Avoid concurrent use.
- Cobimetinib + St. John'S Wort— Strong CYP3A inducer may decrease cobimetinib exposure by >80% and reduce efficacy. Avoid concurrent use.
- Cobimetinib + Voriconazole— Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabr…